Skip to main content
. 2019 Mar 14;216(4):916–935. doi: 10.1084/jem.20171452

Figure 8.

Figure 8.

TAT-Gap19 is neuroprotective in mice subjected to pMCAO. (A) Thionin-stained sections 4 d after pMCAO in WT mice treated with saline, 7.5 μmol/kg i.p. scrambled TAT-GAP19-scrambled, or 0.75 μmol/kg i.p. hemichannel blocker TAT-GAP19 2 h after pMCAO. Black outline highlights the infarct. Scale bar = 2 mm. (B) Infarct volume 4 d after pMCAO from WT mice treated with saline, TAT-GAP19-scrambled, or TAT-GAP19 2 h after pMCAO (one-way ANOVA followed by Tukey’s multiple comparisons test; saline versus scrambled: P > 0.9999; saline versus 0.75 μmol/kg TAT-GAP19: **, P = 0.0021; saline versus 7.5 μmol/kg TAT-GAP19: ****, P = < 0.0001; scrambled versus 0.75 μmol/kg TAT-GAP19: **, P = 0.0019; scrambled versus 7.5 μmol/kg TAT-GAP19: ****, P < 0.0001; 0.75 μmol/kg TAT-GAP19 versus 7.5 μmol/kg TAT-GAP19: *, P = 0.0484; saline: n = 4 mice; 7.5 μmol/kg TAT-GAP19-scrambled: n = 4 mice; 7.5 μmol/kg TAT-GAP19: n = 4 mice; 0.75 μmol/kg TAT-GAP19: n = 4). Error bars represent mean ± SEM.